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TOP CITED PAPERS IN INTERNATIONAL PSYCHOGERIATRICS: 6a. QUALITY OF LIFE FOR
PEOPLE WITH DEMENTIA LIVING IN RESIDENTIAL AND NURSING HOME CARE: THE IMPACT
OF PERFORMANCE ON ACTIVITIES OF DAILY LIVING, BEHAVIORAL AND PSYCHOLOGICAL
SYMPTOMS, LANGUAGE SKILLS, AND PSYCHOTROPIC DRUGS
Reflection
Context of the paper
The majority of people with dementia develop
behavioral and psychological symptoms of dementia
(BPSD) at some point during their illness (Jeste
et al., 2008). These symptoms, which are especially
common among care home residents, are frequently
distressing for the patients who experience them
(Gilley et al., 2006; Jeste et al., 2008) and proble-
matic for their professional and/or family caregivers.
The starting point for our paper “Quality of life
for people with dementia living in residential and
nursing home care: the impact of performance on
activities of daily living, behavioral and psycholo-
gical symptoms, language skills, and psychotropic
drugs” (Ballard et al., 2001) was to try and
understand the impact of BPSD, function and
language skills on quality of life in care home
residents with dementia. Although there were
frequent statements in previous work referring to
the capacity of psychiatric and behavioral symptoms
to reduce quality of life, we had been unable
to identify any empirical evidence to support
this clinical impression in a thorough literature
review. The parallel validation of Dementia
Care Mapping (DCM), predominantly a practice
development tool, as an observational measure
of well-being/quality of life (Kitwood and Bredin,
1997; Fossey et al., 2002) provided an excellent
opportunity to examine this issue in a care home
setting. The study focused on 209 people with
dementia living in residential and nursing home
care in north-east England in the U.K., who
received a detailed assessment of BPSD, function
and cognition. A DCM evaluation was completed
for 112 of these individuals, providing a detailed
observational measure of well-being, activities and
social withdrawal as indices of quality of life
over a six-hour daytime period. To our surprise,
there was actually no association between well-
being, social withdrawal or activities and BPSD. In
contrast, there was a significant association between
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antipsychotic medication and reduced well-being,
social withdrawal and activities respectively, even
after controlling for the severity of behavioral
disturbance. Using an arbitrary definition of “ill-
being”, defined as a well-being score of less than
zero, 5% of people not taking antipsychotics, 10%
of people taking atypical antipsychotics and 22% of
people taking typical antipsychotics were defined as
having ill-being. Lower levels of functional ability
were also associated with significantly lower well-
being, less activities and more social withdrawal.
At first this latter finding appears to be contrary to
one of the central principles of DCM – namely,
that the assessment should be independent of
dementia severity. Although high levels of well-
being and engagement are possible for people with
severe dementia, this probably requires higher staff
numbers and a workforce with more specialized
skills in order to achieve this.
Antipsychotics and quality of life
There have been eight placebo controlled trials of
typical antipsychotics and 18 placebo controlled
trials of atypical antipsychotics for the treatment of
BPSD (Ballard and Howard, 2006; Schneider et al.,
2006), none of which directly measured the impact
of treatment on quality of life. There had been
a covert assumption that improving BPSD would
automatically improve quality of life. The findings
in our 2001 paper in International Psychogeriatrics
challenged this assumption, and actually suggested
that treatment with antipsychotics may have a
more detrimental impact on quality of life than
the symptoms for which they were prescribed.
The interest in the paper has probably stemmed
from this identification of an association between
antipsychotic prescription and impaired quality
of life in people with dementia. This does have
important implications for clinical practice as the
potential adverse consequences of treatment are
much more difficult to justify in the absence of
direct benefits in quality of life to the individual,
and it provides support for the argument that the
use of atypical antipsychotics should be restricted to
situations where there is direct risk to the individual
or others as a result of the BPSD.
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There are still very few studies that have ex-
amined the relationship between quality of life and
antipsychotic drug use, particularly in the context
of randomized controlled clinical trials. We have
subsequently reported a small comparative trial
of 48 patients suggesting improvements in the
quality of life in patients with Alzheimer’s disease
who were switched from a typical antipsychotic
to quetiapine (Ballard and Margallo-Lana, 2002).
Although the limited evidence of efficacy does limit
the potential value of quetiapine, this is probably
helpful in indicating that atypical agents have a less
detrimental impact on quality of life than typical
antipsychotics. Important studies have highlighted
the potential of specific non-pharmacological
intervention programs to improve key outcomes
such as the use of unnecessary antipsychotic drugs
(Rovner et al. 1996; Ballard et al., 2002; Fossey
et al., 2006), mood (Teri et al., 1997; 2003)
and behavioral symptoms (Cohen-Mansfield et al.,
2007) with person-centered training for care
staff, or structured approaches such as exercise,
social interaction, pleasant events or assessment of
needs, but disappointingly few studies have directly
evaluated the impact of these interventions on
quality of life directly, or the impact of stopping
antipsychotics on quality of life amongst care home
residents with dementia. The Focused Intervention
Training and Support (FITS) study, in a cluster
randomized trial, demonstrated the capacity of a
training program focused on person-centered care
to significantly reduce the use of antipsychotic
drugs in care homes (Fossey et al., 2006). A
secondary analysis of individuals participating in
the FITS study who stopped antipsychotics over
the course of the trial has been completed for the
present paper. Over the course of the study, a
consultant old age psychiatrist and a senior member
of nursing staff from each home reviewed the drug
prescriptions of the residents after completion of
the baseline assessments and every three months
over the course of the study following good
practice guidelines (Howard et al., 2001). DCM
was used to evaluate quality of life (QoL) indices
(Kitwood and Bredin, 1997), and has been shown
to have good test-re-test reliability (Fossey et al.,
2002). The Cohen-Mansfield Agitation Inventory
(CMAI; Cohen-Mansfield et al., 1989) was used
to measure the reported agitated and disruptive
behaviors of residents. Assessments at 12 months
were carried out as far as possible blind to each
home’s intervention: the trial staff did not identify
the intervention homes to the researcher, and
nursing home staff were asked not to discuss their
home’s intervention with the researcher. Despite
these efforts, because the package was designed
to influence the whole care approach of staff, it
is likely that the research assistant would have
been able to detect which homes had received the
intervention. For the current analysis we compared
changes in three QoL indices over the course of the
study (social withdrawal, positive activities, well-
being) between baseline and follow-up using a
paired sample t test for all residents discontinuing
antipsychotics over the study period. All analyses
were carried out using SPSS version 15. Forty nine
Table 1. Changes in quality of life indices in residents stopping antipsychotics from the FITS trial
FOLLOW-U P E VA L UAT I O N
(BASELINE VS
N = 42 BASEL INE F ITS CONTROL F OLL OW-U P)
.........................................................................................................................................................................................................................................................................................................................
Social withdrawal 6.64 SD 8.96 −5.24 SD 13.56 −1.29 SD 5.42 T 2.1 P = 0.04∗
Type 1 behaviors +34.74 SD 19.53 +13.44 SD 23.73 +1.47 SD 24.29 T 2.3 P = 0.03∗
Well-being 0.65 SD 0.69 +0.34 SD 0.59 +0.15 SD 0.98 T 2.2 P = 0.03∗
FITS = Focused Intervention Training and Support. ∗ Statistically significant, p < 0.05.
Table 2. Relationship of agitation and aggression with quality of life indices from the
FITS trial
SOCIAL WITHDRAWAL WELL -BEING
................................................................................................................................................................................................................................................
Whole cohort (n = 305)
Total CMAI R = −0.04 P = 0.48 R = 0.02 P = 0.68
CMAI physical aggression score R = −0.02 P = 0.73 R = −0.05 P = 0.44
Quartile with highest levels of agitation
Total CMAI R = 0.05 P = 0.68 R = −0.01 P = 0.91
CMAI physical aggression score R = −0.03 P = 0.78 R = −0.15 P = 0.23
All correlations completed using Pearson’s R.
FITS = Focused Intervention Training and Support; CMAI = Cohen-Mansfield Agitation Inventory.
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of these residents stopped antipsychotics between
the baseline and 12-month assessments (32 FITS,
17 controls), of whom 42 were evaluated with DCM
(25 FITS, 17 control). Stopping antipsychotics
was associated with a significant reduction in
social withdrawal, a significant improvement in
well-being and a significant increase in positive
activities (Table 1). This does provide some further
evidence that the discontinuation of antipsychotics
according to best practice guidelines does improve
quality of life for people with dementia receiving
these treatments. However, it is imperative that
further intervention studies, both pharmacological
and non-pharmacological, evaluating treatments for
BPSD include a direct measure of quality of life
amongst the study outcomes.
BPSD and quality of life
To take the issue full circle, it is clear from our
2001 paper that, overall, there was no significant
association between BPSD and quality of life. Our
clinical interpretation of this finding was that it was
probably explained by the fact that the majority
of BPSD are mild to moderate in severity and do
not have a major impact on quality of life. This
gives a clear message that treating mild-moderate
BPSD with antipsychotics is unlikely to improve
the quality of life of these individuals. The key
question for clinical practice, however, is whether
there is a small group of patients with much more
severe and distressing BPSD that clearly do have
a significant impact on their quality of life. From
the database of the FITS study, we have also
been able to examine the relationship between
agitation/aggression and the key QoL indices from
the baseline evaluations of 305 participants with
dementia (assessments as described in the previous
paragraph). We evaluated the association between
BPSD and both the total score and the score
for physical aggression on the CMAI. In addition
we repeated the analysis selecting individuals in
the highest quartile on the total CMAI (cut-off
score ≥48) and the highest quartile for physical
aggression (cut-off score ≥15). All evaluations were
undertaken using SPSS version 15. Consistent with
the findings of our 2001 paper, there was no
overall association between agitation or aggression
and either well-being or social withdrawal. More
surprisingly, however, there was still no suggestion
of an association between agitation/aggression and
well-being or social withdrawal, even in the quartile
with the most severe symptoms (Table 2). Clearly,
there is a need to better understand the relationship
between quality of life and BPSD for individuals
with dementia as this is a key part of determining
the optimal treatment for a particular patient and
of weighing up the balances of different treatment
approaches. What the current data seem to indicate
is that severity of BPSD alone may not be sufficient
to impact upon the quality of life of the person
experiencing them, and a more careful evalu-
ation of whether there is a specific impact on
quality of life for a particular individual is probably
needed. Important – but separate – issues are the
impact on the quality of life of carergivers and
the risk to the person or others, which also have
to be balanced when making clinical treatment
decisions.
In summary, our original 2001 paper highlighted
a relationship between antipsychotics and quality of
life, and the absence of a straightforward direct link
between quality of life and BPSD. Further analysis
completed as part of the current paper reinforces
these conclusions. The modest progress since 2001
in understanding the relationship between BPSD
and quality of life and the continuing absence of
quality of life measures in BPSD treatment studies
is disappointing. These are key questions to inform
treatment decisions in clinical practice.
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Commentary
One of the beauties of research is that it never fails
to surprise us. Often the unintended findings are
the ones which influence future research directions
and clinical practice more than predicted research
results. One such an example is the landmark
paper from Ballard and colleagues reporting the
detrimental effect of antipsychotic medication on
quality of life of older adults with dementia
living in residential care (Ballard et al., 2001). As
pointed out in the above Reflection, the aim of
this research was to demonstrate that behavioral
and psychological symptoms of dementia (BPSD)
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directly impact on quality of life. Surprisingly, this
could not be confirmed, but instead antipsychotic
medication was identified as the culprit which
negatively affected quality of life. It is not surprising
that these findings caused this publication to
be catapulted into the illustrious group of top-
cited papers in International Psychogeriatrics. It
confirmed frequent observations from clinicians
and underscored widely held unease about using
these drugs for treating BPSD, long before the
increased risk for cerebrovascular events for the
same group of drugs and patients made the head-
lines. It is exciting that Ballard and colleagues in
their reflection now present additional new data
confirming their 2001 findings and even going
one step further to report improved quality of life
in patients with dementia for whom antipsychotic
medication could be stopped.
The puzzling question remains why the presence
of BPSD does not seem to impact directly on quality
of life even in the more severe forms. It seems to
act as a reminder that BPSD are complex clinical
phenomena about which our knowledge is still very
limited. However, surprising research results often
trigger creativity to look at a problem from a new,
in this case more pragmatic, angle. The findings
from Ballard and colleagues might suggest that a
way forward is to focus next on what types of
intervention can directly improve quality of life in
residents and carers of residential care facilities (e.g.
stopping antipsychotic medication).
Well-performed clinical studies with a large
enough sample size to provide meaningful results in
this area of psychogeriatrics were rare in 2001 and
are still rare in 2009. This highlights the ongoing
challenges involved in conceptualizing a feasible
research plan and then of securing adequate funding
to conduct the research in residential care facilities
which, in many countries, struggle to maintain good
quality dementia care due to financial limitations
as well as the heavy burden of time constraints on
overworked and underpaid staff. The findings of
Ballard and colleagues, as well as the additional
results presented in their Reflection above, should
remind us that the community of researchers and
clinicians working in psychogeriatrics needs to con-
tinue to lobby both for more support for research
and for improved clinical care for the benefit
of those with dementia and those caring for them.
No doubt, for the time being, antipsychotic drugs
will continue to have their place in clinical scenarios
where they are needed to manage acute risk to
the patient or those providing care. However, the
mounting evidence that antipsychotic medications
have many harmful consequences when given to pa-
tients with dementia should encourage researchers,
as well as funding agencies, to focus on exploring
non-pharmacological interventions which are
suitable for use in residential care. The move away
from antipsychotic medications, which too often are
considered a “quick and easy fix” to manage difficult
behavior, especially in acute hospital settings but
also in residential care, and to replace them with
effective and safe non-pharmacological interven-
tions requires a paradigm shift for everyone involved
in dementia care. The paper by Ballard et al.
(2001) was crucial to get us on the right track.
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